2026 Q1 -tulosraportti
Vain PDF
98 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 25.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
1 päivä sittenPitäisi varmaankin ostaa lisää.
May one wish that you elaborate on your comments? What do you think happens next? Why should you add more right now?
·30.7.I'm pretty sure that NanoEcho has not submitted a full application to EIC neither on May 6th nor here in July, hope they are aiming for September 2nd instead, then we should have an answer after final interview 8-9 thereafter. I can see that 37 companies out of 83 that proceeded to interview, received Grant from EIC from the first application in 2026.- ·29.7.Finally a stock I believe in for the future If they can't progress at some point, they will sell it on I throw in 100 kr every month I'm up to 35.000 kr now for pocket money XXX
- ·29.7.Just for those who are a bit curious Here are the details about NanoEcho AB’s US patents and status, as well as the next steps in their clinical trials.1. Details about the US patentsNanoEcho is working purposefully to protect its technology in strategic markets, including the USA, which accounts for approximately 40 percent of the global market for medical devices.Approved design and hardware patent (April 2026): NanoEcho recently received an official "Decision to Grant" in the USA for a key patent that protects the very design of the company's handheld ultrasound probe. The patent covers the unique integration and physical placement of ultrasound transducers and magnetic components in the company's ultrasound probe.Strategic flexibility: This patent also includes alternative designs of the probe. This means that the company can more easily adapt the technology to other clinical areas beyond rectal cancer in the future.The basic method patent: The company's fundamental method patent – which protects the method itself of combining magnets and ultrasound scanning on the same device – was approved in the USA in 2023. It has already been approved in, among others, Europe, Japan, South Korea, and Canada.2. Next steps in the clinical trialsThe purpose of NanoEcho's clinical program is to create the necessary documentation to obtain market approval for both the medical device and their associated nanoparticles (NanoEcho Particle-1 / NEP-01).Results from initial PoC study (June 2026): NanoEcho published in June 2026 the results from the initial, exploratory phase of their Proof of Concept (PoC) study conducted on healthy volunteers.Technical success, but dose adjustment required: System adaptations showed good image quality, and the system functioned more intuitively. However, the study did not achieve its primary endpoint in terms of validating the predetermined dose of nanoparticles and the timing of the examination itself.The next steps: Since the study is exploratory, NanoEcho is now using the data to evaluate and make further adjustments to the dose and timing. The next major step in the clinical program will be to roll out the study to the next planned phase, where the equipment will be tested on actual patients with rectal cancer (including at CTC in Uppsala). The capital from the rights issue in February 2026 is specifically allocated to finance these next clinical phases.If you wish, I can investigate the company's timeline for CE marking in Europe or provide an update on their competitors in advanced cancer diagnostics.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
98 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittenPitäisi varmaankin ostaa lisää.May one wish that you elaborate on your comments? What do you think happens next? Why should you add more right now?
- ·30.7.I'm pretty sure that NanoEcho has not submitted a full application to EIC neither on May 6th nor here in July, hope they are aiming for September 2nd instead, then we should have an answer after final interview 8-9 thereafter. I can see that 37 companies out of 83 that proceeded to interview, received Grant from EIC from the first application in 2026.
- ·29.7.Finally a stock I believe in for the future If they can't progress at some point, they will sell it on I throw in 100 kr every month I'm up to 35.000 kr now for pocket money XXX
- ·29.7.Just for those who are a bit curious Here are the details about NanoEcho AB’s US patents and status, as well as the next steps in their clinical trials.1. Details about the US patentsNanoEcho is working purposefully to protect its technology in strategic markets, including the USA, which accounts for approximately 40 percent of the global market for medical devices.Approved design and hardware patent (April 2026): NanoEcho recently received an official "Decision to Grant" in the USA for a key patent that protects the very design of the company's handheld ultrasound probe. The patent covers the unique integration and physical placement of ultrasound transducers and magnetic components in the company's ultrasound probe.Strategic flexibility: This patent also includes alternative designs of the probe. This means that the company can more easily adapt the technology to other clinical areas beyond rectal cancer in the future.The basic method patent: The company's fundamental method patent – which protects the method itself of combining magnets and ultrasound scanning on the same device – was approved in the USA in 2023. It has already been approved in, among others, Europe, Japan, South Korea, and Canada.2. Next steps in the clinical trialsThe purpose of NanoEcho's clinical program is to create the necessary documentation to obtain market approval for both the medical device and their associated nanoparticles (NanoEcho Particle-1 / NEP-01).Results from initial PoC study (June 2026): NanoEcho published in June 2026 the results from the initial, exploratory phase of their Proof of Concept (PoC) study conducted on healthy volunteers.Technical success, but dose adjustment required: System adaptations showed good image quality, and the system functioned more intuitively. However, the study did not achieve its primary endpoint in terms of validating the predetermined dose of nanoparticles and the timing of the examination itself.The next steps: Since the study is exploratory, NanoEcho is now using the data to evaluate and make further adjustments to the dose and timing. The next major step in the clinical program will be to roll out the study to the next planned phase, where the equipment will be tested on actual patients with rectal cancer (including at CTC in Uppsala). The capital from the rights issue in February 2026 is specifically allocated to finance these next clinical phases.If you wish, I can investigate the company's timeline for CE marking in Europe or provide an update on their competitors in advanced cancer diagnostics.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 25.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
98 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 25.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 30.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittenPitäisi varmaankin ostaa lisää.May one wish that you elaborate on your comments? What do you think happens next? Why should you add more right now?
- ·30.7.I'm pretty sure that NanoEcho has not submitted a full application to EIC neither on May 6th nor here in July, hope they are aiming for September 2nd instead, then we should have an answer after final interview 8-9 thereafter. I can see that 37 companies out of 83 that proceeded to interview, received Grant from EIC from the first application in 2026.
- ·29.7.Finally a stock I believe in for the future If they can't progress at some point, they will sell it on I throw in 100 kr every month I'm up to 35.000 kr now for pocket money XXX
- ·29.7.Just for those who are a bit curious Here are the details about NanoEcho AB’s US patents and status, as well as the next steps in their clinical trials.1. Details about the US patentsNanoEcho is working purposefully to protect its technology in strategic markets, including the USA, which accounts for approximately 40 percent of the global market for medical devices.Approved design and hardware patent (April 2026): NanoEcho recently received an official "Decision to Grant" in the USA for a key patent that protects the very design of the company's handheld ultrasound probe. The patent covers the unique integration and physical placement of ultrasound transducers and magnetic components in the company's ultrasound probe.Strategic flexibility: This patent also includes alternative designs of the probe. This means that the company can more easily adapt the technology to other clinical areas beyond rectal cancer in the future.The basic method patent: The company's fundamental method patent – which protects the method itself of combining magnets and ultrasound scanning on the same device – was approved in the USA in 2023. It has already been approved in, among others, Europe, Japan, South Korea, and Canada.2. Next steps in the clinical trialsThe purpose of NanoEcho's clinical program is to create the necessary documentation to obtain market approval for both the medical device and their associated nanoparticles (NanoEcho Particle-1 / NEP-01).Results from initial PoC study (June 2026): NanoEcho published in June 2026 the results from the initial, exploratory phase of their Proof of Concept (PoC) study conducted on healthy volunteers.Technical success, but dose adjustment required: System adaptations showed good image quality, and the system functioned more intuitively. However, the study did not achieve its primary endpoint in terms of validating the predetermined dose of nanoparticles and the timing of the examination itself.The next steps: Since the study is exploratory, NanoEcho is now using the data to evaluate and make further adjustments to the dose and timing. The next major step in the clinical program will be to roll out the study to the next planned phase, where the equipment will be tested on actual patients with rectal cancer (including at CTC in Uppsala). The capital from the rights issue in February 2026 is specifically allocated to finance these next clinical phases.If you wish, I can investigate the company's timeline for CE marking in Europe or provide an update on their competitors in advanced cancer diagnostics.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt